KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2016 - 2026)

Esperion Therapeutics filings provide 6 years of Amortization of Deferred Charges readings, the most recent being -$9.8 million for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 5801.16% to -$9.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 502.58% increase, with the full-year FY2025 number at $9.1 million, up 507.01% from a year prior.
  • Amortization of Deferred Charges hit -$9.8 million in Q4 2025 for Esperion Therapeutics, down from $9.1 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $9.1 million in Q2 2025 to a low of -$9.8 million in Q4 2025.
  • Median Amortization of Deferred Charges over the past 5 years was $408500.0 (2021), compared with a mean of $692200.0.
  • The widest YoY moves for Amortization of Deferred Charges: up 2175.0% in 2025, down 5801.16% in 2025.
  • Esperion Therapeutics' Amortization of Deferred Charges stood at $407000.0 in 2021, then grew by 1.72% to $414000.0 in 2022, then crashed by 405.8% to -$1.3 million in 2023, then soared by 113.59% to $172000.0 in 2024, then crashed by 5801.16% to -$9.8 million in 2025.
  • The last three reported values for Amortization of Deferred Charges were -$9.8 million (Q4 2025), $9.1 million (Q3 2025), and $9.1 million (Q2 2025) per Business Quant data.